Mr Saransh’s Expert Insights Featured in BioSpectrum India

We’re proud to share that expert insights from Mr. Saransh Chaudhary, President – Global Critical Care & CEO – VMRC,  have been featured in BioSpectrum India, showcasing his expert views on the rapidly evolving GLP-1 drug market. As the Indian pharmaceutical industry braces for a major shift with the patent expiry of drugs like Semaglutide by March 2026, Mr. Saransh highlighted the critical opportunity this creates for Indian companies.

This feature highlights how  eminent patents can democratize access to life-changing treatments for diabetes and obesity. With India’s legacy in producing affordable generics and biosimilars, local firms are well-positioned to make advanced GLP-1 therapies more accessible globally.

However, he also addressed the challenges ahead—legal battles, innovation pressures, and the need for advanced R&D capabilities to meet regulatory standards. Mr. Saransh emphasized a balanced approach: protecting innovation while ensuring equitable access to healthcare.

This feature in BioSpectrum reflects the growing voice of Indian pharma leadership in global healthcare discussions.